Phase II randomized, open-label study of cetuximab (Cet) and bevacizumab (Bev) in combination with paclitaxel (P) and carboplatin (C) in patients with stageIII/IV non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Bonomi, P. D. [1 ]
Mace, J. [1 ]
Mandanas, R. D. [1 ]
Min, M. [1 ]
Zhang, Y. [1 ]
Rowinsky, E. [1 ]
Youssoufian, H. [1 ]
机构：
[1] Rush Univ, Ctr Med, Chicago, IL 60612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8046
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PHASE II RANDOMIZED, OPEN-LABEL STUDY OF CETUXIMAB (CET) AND BEVACIZUMAB (BEV) IN COMBINATION WITH PACLITAXEL (P) AND CARBOPLATIN (C) IN PATIENTS WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)
    Bonomi, Philip
    Mace, Joseph
    Mandana, Romeo
    Min, Myo
    Mark, Olsen
    Youssoufian, Hagop
    Katz, Terry
    Simms, Lorinda
    Lee, Hyun Jung
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1292 - S1292
  • [2] Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC)
    Blumenschein, G. R.
    Kabbinavar, F. F.
    Menon, H.
    Mok, T.
    Stephenson, J.
    Beck, J. T.
    Lakshmaiah, K.
    Kracht, K.
    Sikorski, R. S.
    Schwartzberg, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Randomized, open-label phase 2 study of safety and efficacy of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC)
    Blumenschein, Jr George
    Kabbinavar, Fairooz
    Menon, Hari
    Mok, Tony S. K.
    Stephenson, Joe J.
    Beck, J. Thaddeus
    Lakshmaiah, Kuntegowdanahalli
    Reckamp, Karen
    Hei Yong-jiang
    Kracht, Karolyn
    Sikorski, Robert
    Schwartzberg, Leee
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S354 - S355
  • [4] Motesanib or bevacizumab in combination with paclitaxel and carboplatin in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): interim results from a randomized, open-label, phase 2 study
    Blumenschein, G., Jr.
    Schwartzberg, L. S.
    Menon, H.
    Mok, T. S. K.
    Stephenson, J. J.
    Beck, J. T.
    Lakshmaiah, K.
    Kracht, K.
    Sikorski, R.
    Kabbinavar, F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 555 - 555
  • [5] A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small lung cancer (NSCLC)
    Blackhall, F. H.
    Mark, Z.
    Zatloukal, P.
    Szima, B.
    Albert, I.
    Juhasz, E.
    Yang, X.
    Smethurst, D.
    Hei, Y.
    Soria, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
    Blumenschein, G. R., Jr.
    Kabbinavar, F.
    Menon, H.
    Mok, T. S. K.
    Stephenson, J.
    Beck, J. T.
    Lakshmaiah, K.
    Reckamp, K.
    Hei, Y. -J.
    Kracht, K.
    Sun, Y. -N.
    Sikorski, R.
    Schwartzberg, L.
    ANNALS OF ONCOLOGY, 2011, 22 (09) : 2057 - 2067
  • [7] A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC)
    Fidias, P.
    Ciuleanu, T. A.
    Gladkov, O.
    Manikhas, G. M.
    Bondarenko, I. N.
    Pluzanska, A.
    Ramlau, R.
    Lynch, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [8] Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907
    Nishio, M.
    Horai, T.
    Kunitoh, H.
    Ichinose, Y.
    Nishiwaki, Y.
    Hida, T.
    Yamamoto, N.
    Kawahara, M.
    Saijo, N.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC)
    William, W. N., Jr.
    Kies, M. S.
    Fossella, F. V.
    Gladish, G.
    Heymach, J. V.
    Glisson, B. S.
    Tse, W. H.
    Liu, D.
    Herbst, R. S.
    Lippman, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer
    Bonomi, Philip D.
    Mace, Joseph
    Mandanas, Romeo A.
    Min, Myo
    Olsen, Mark
    Youssoufian, Hagop
    Katz, Terry L.
    Sheth, Grishma
    Lee, Hyun Jung
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 338 - 345
12345